Medical Developments International 미래 성장

Future 기준 확인 4/6

Medical Developments International (는) 각각 연간 93.1% 및 14.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 94.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7% 로 예상됩니다.

주요 정보

93.1%

수익 성장률

94.3%

EPS 성장률

Pharmaceuticals 수익 성장	36.9%
매출 성장률	14.4%
향후 자기자본 수익률	7.0%
애널리스트 커버리지	Low
마지막 업데이트	25 Oct 2024

최근 미래 성장 업데이트

Recent updates

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

May 13

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

May 03

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Mar 11

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Jan 16

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Jan 03

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Aug 09

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

Apr 24

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Jul 04

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Mar 04

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Mar 05

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

Feb 07

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Dec 16

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Dec 10

수익 및 매출 성장 예측

ASX:MVP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	55	4	4	7	1
6/30/2026	48	0	5	7	1
6/30/2025	41	-4	1	3	1
6/30/2024	33	-41	-14	-11	N/A
3/31/2024	33	-30	-17	-12	N/A
12/31/2023	34	-19	-21	-15	N/A
9/30/2023	33	-12	-23	-16	N/A
6/30/2023	32	-6	-24	-16	N/A
3/31/2023	29	-4	-22	-16	N/A
12/31/2022	26	-2	-20	-15	N/A
9/30/2022	24	-7	-18	-13	N/A
6/30/2022	22	-12	-16	-11	N/A
3/31/2022	22	-16	-17	-10	N/A
12/31/2021	22	-19	-17	-10	N/A
9/30/2021	24	-16	-16	-9	N/A
6/30/2021	25	-13	-15	-9	N/A
3/31/2021	25	-7	-14	-8	N/A
12/31/2020	24	-1	-13	-6	N/A
9/30/2020	23	0	-11	-3	N/A
6/30/2020	23	0	-9	0	N/A
3/31/2020	22	1	-8	1	N/A
12/31/2019	22	1	-8	1	N/A
9/30/2019	22	1	2	11	N/A
6/30/2019	21	1	11	21	N/A
3/31/2019	20	1	12	22	N/A
12/31/2018	19	0	12	23	N/A
9/30/2018	18	0	2	12	N/A
6/30/2018	17	0	-9	2	N/A
3/31/2018	18	1	N/A	2	N/A
12/31/2017	18	2	N/A	3	N/A
9/30/2017	18	2	N/A	3	N/A
6/30/2017	18	2	N/A	4	N/A
3/31/2017	18	2	N/A	4	N/A
12/31/2016	18	2	N/A	4	N/A
9/30/2016	17	2	N/A	8	N/A
6/30/2016	15	2	N/A	12	N/A
3/31/2016	14	1	N/A	12	N/A
12/31/2015	12	1	N/A	13	N/A
9/30/2015	12	1	N/A	8	N/A
6/30/2015	12	2	N/A	3	N/A
3/31/2015	11	1	N/A	3	N/A
12/31/2014	10	1	N/A	3	N/A
9/30/2014	10	1	N/A	2	N/A
6/30/2014	9	1	N/A	1	N/A
3/31/2014	10	1	N/A	1	N/A
12/31/2013	10	1	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MVP 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: MVP (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: MVP 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: MVP 의 수익(연간 14.4% ) Australian 시장( 5.8% 보다 빠르게 성장할 것으로 예상됩니다. 5.8% 연간).

고성장 수익: MVP 의 수익(연간 14.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MVP 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 7 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 00:40
장 마감 주가	2024/12/20 00:00
수익	2024/06/30
연간 수익	2024/06/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Medical Developments International Limited 5 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Dennis Hulme	APP Securities Pty Ltd.
Anubhav Saxena	Bell Potter
Martyn Jacobs	Canaccord Genuity

Medical Developments International 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates upgraded to AU$0.033 loss

Price target increased by 38% to AU$3.03

Price target decreased by 29% to AU$1.60

Price target decreased to AU$4.30

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Consensus forecasts updated

Recent updates

Medical Developments International Limited Announces Resignation of Mary Sontrop from the Board, Effective December 20, 2024

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Consensus EPS estimates upgraded to AU$0.033 loss

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

Price target increased by 38% to AU$3.03

New minor risk - Profitability

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Price target decreased by 29% to AU$1.60

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

New minor risk - Financial data availability

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Medical Developments International Limited Discontinues China Clinical Trials

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Price target decreased to AU$4.30

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Medical Developments International Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022

No independent directors

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Medical Developments International Limited Announces That US Food and Drug Administration Lifts Clinical Hold on Penthrox

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Medical Developments International Limited to Report Q2, 2022 Results on Feb 24, 2022

Non-Executive Chairman recently bought AU$306k worth of stock

Non-Executive Chairman recently bought AU$1.0m worth of stock

Full year 2021 earnings released: AU$0.18 loss per share (vs AU$0.006 profit in FY 2020)

Medical Developments International Limited Provides Sales Guidance for the Fiscal Year 2022

Price target decreased to AU$6.18

Medical Developments International Limited Announces Earnings Guidance for the Year Ended June 30, 2021

Non-Executive Chairman recently bought AU$534k worth of stock

Medical Developments International Limited Appoints Mary Sontrop as Non-Executive Director

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Analysts lower EPS estimates to -AU$0.037

Revenue and earnings miss expectations

First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.004 profit in 1H 2020)

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

New 90-day high: AU$7.18

Price target raised to AU$7.25

Analysts lower EPS estimates to -AU$0.018

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Medical Developments International Limited Announces Executive Changes

New 90-day high: AU$6.61

Price target lowered to AU$6.97

Analysts lower EPS estimates to -AU$0.022

Medical Developments International Limited Appoints Brent Macgregor as Chief Executive Officer, Effective November 1, 2020

Analysts update estimates

Medical Developments International Limited Declares No Dividend for the Full Year Ended 30 June 2020

New 90-day low: AU$5.29